Lanvis (Tioguanine)

Tioguanine is a purine analog that is metabolized inside cells to thioguanine nucleotides. These nucleotides become incorporated into DNA and RNA, disrupting purine synthesis, leading to cytotoxicity in rapidly dividing cells and suppressing immune cell proliferation.

The dose of Lanvis is individualized by the prescribing physician based on the specific indication, patient weight, renal and hepatic function, and treatment protocol. Clinicians calculate the appropriate amount and schedule, and patients should follow the prescribed regimen exactly.

The safety of tioguanine during pregnancy or lactation has not been definitively established. It should only be used if the potential benefits justify the potential risks to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Lanvis product page at gnhindia.com, providing the required quantity and institutional credentials. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional verification before supplying pricing, availability, shipping details, and any necessary import documentation.

The primary alternative to tioguanine is mercaptopurine, another purine analog used in similar hematologic and inflammatory conditions. While both agents inhibit purine synthesis, tioguanine may have a different toxicity profile and dosing schedule; selection depends on patient tolerance, disease characteristics, and physician preference.

Lanvis should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to excessive heat or humidity, which could compromise stability.

Lanvis is taken orally, typically as a tablet, with or without food as directed by the prescribing clinician. The exact administration schedule, such as daily or intermittent dosing, is determined by the treating physician based on the therapeutic goal and patient response.

The most serious risks include severe myelosuppression leading to life‑threatening infections or bleeding, hepatic toxicity, pancreatitis, and the potential development of secondary malignancies. Patients should be monitored regularly for blood counts, liver enzymes, and any signs of infection or organ dysfunction.

Lanvis is contraindicated in patients with known hypersensitivity to tioguanine or other purine analogs, those with severe hepatic impairment, and individuals with active uncontrolled infections. Caution is also advised for patients with significant bone marrow suppression or those receiving other myelosuppressive therapies.